Alglucosidase alfa
Contents
Description
Alglucosidase alfa is a recombinant human acid alpha-glucosidase enzyme replacement therapy. It is indicated for the treatment of Pompe disease (glycogen storage disease type II), including infantile-onset forms that can present with severe cardiomyopathy. The enzyme catalyzes the hydrolysis of glycogen to glucose in lysosomes.
Indications & Therapeutic Use
Pompe disease, glycogen storage disease type II, infantile-onset Pompe disease with cardiomyopathy
Linked Diseases:
Global Availability (7 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Alglucosidase alfa — GNH India
11 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Browse all Alglucosidase alfa products on GNH IndiaProducts and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | alglucosidase alfa |
| Brands | 1 brand available |
| Active Ingredient | alglucosidase alfa |
| Drug Class | Pompe disease |
| Manufacturer | Sanofi Genzyme |
| Dosage Forms | IV infusion, 50mg vial for reconstitution |
| Medical Code | A16AB07 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Required |
| Lead Time | 7 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00158600 |
| Countries | 7 countries |